HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance.

Joseph R. Leventhal, James M. Mathew, Suzanne Ildstad, Daniel R. Salomon, Sunil M. Kurian, Manikkam Suthanthiran, Anat Tambur, John Friedewald, Lorenzo Gallon, Jane Charette, Josh Levitsky, Yashpal Kanwar, Michael Abecassis, Joshua Miller

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In this chapter, we describe studies on non-chimeric human leukocyte antigen (HLA) identical tolerance and chimeric HLA disparate tolerance brought about by infusions of hematopoietic stem cells from the renal donor (DHSC). In our HLA identical series, 4 DHSC infusions were administered during the first 9 months posttransplant in a highly immunoregulatory environment using alemtuzumab induction and rapid conversion from early tacrolimus to mycophenolate and sirolimus. This resulted in the generation of recipient T regulatory cells accompanied by genomic indicators, but only transient chimerism. Seven of the first 12 recipients have been immunosuppression-free between 1 1/2 - 4 years with transplant biopsies free of rejection one year after immunosuppression withdrawal. The HLAdisparate group was treated by non-myeloablative conditioning consisting of: 200cGy whole body irradiation; fludarabine; cyclophosphamide; and, perioperative infusion of a product termed FCRx that contained DHSC, T cells, and a unique fraction of bone marrow derived CD8+TCR-alphabeta-negative cells. Five of the first 8 subjects became 100% chimeric in the peripheral blood and have been immunosuppression-free for 2 to 4 years without graft-versus-host-disease and with normal function and transplant biopsies. An additional 12 recipients with shorter follow-up have had similar courses. Those with non-durable chimerism have not been able to have immunosuppression withdrawn but maintain normal renal transplant function. We conclude that non-HLA disparities in renal transplants between HLA identical pairs may not need durable chimerism to induce tolerance provided by DHSC and temporary immunosuppression supporting the development of regulatory T cells. However, more intense conditioning and infusion of FCRx leading to durable chimerism in the absence of graft versus host disease is necessary to induce tolerance in HLA disparate pairs.

Original languageEnglish
Pages (from-to)145-156
Number of pages12
JournalClinical transplants
Publication statusPublished - 1 Jan 2013
Externally publishedYes

Fingerprint

HLA Antigens
Chimerism
Immunosuppression
Transplants
Kidney
Graft vs Host Disease
Regulatory T-Lymphocytes
Biopsy
Whole-Body Irradiation
Tacrolimus
Sirolimus
Hematopoietic Stem Cells
Cyclophosphamide
Bone Marrow
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Leventhal, J. R., Mathew, J. M., Ildstad, S., Salomon, D. R., Kurian, S. M., Suthanthiran, M., ... Miller, J. (2013). HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance. Clinical transplants, 145-156.

HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance. / Leventhal, Joseph R.; Mathew, James M.; Ildstad, Suzanne; Salomon, Daniel R.; Kurian, Sunil M.; Suthanthiran, Manikkam; Tambur, Anat; Friedewald, John; Gallon, Lorenzo; Charette, Jane; Levitsky, Josh; Kanwar, Yashpal; Abecassis, Michael; Miller, Joshua.

In: Clinical transplants, 01.01.2013, p. 145-156.

Research output: Contribution to journalArticle

Leventhal, JR, Mathew, JM, Ildstad, S, Salomon, DR, Kurian, SM, Suthanthiran, M, Tambur, A, Friedewald, J, Gallon, L, Charette, J, Levitsky, J, Kanwar, Y, Abecassis, M & Miller, J 2013, 'HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance.', Clinical transplants, pp. 145-156.
Leventhal JR, Mathew JM, Ildstad S, Salomon DR, Kurian SM, Suthanthiran M et al. HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance. Clinical transplants. 2013 Jan 1;145-156.
Leventhal, Joseph R. ; Mathew, James M. ; Ildstad, Suzanne ; Salomon, Daniel R. ; Kurian, Sunil M. ; Suthanthiran, Manikkam ; Tambur, Anat ; Friedewald, John ; Gallon, Lorenzo ; Charette, Jane ; Levitsky, Josh ; Kanwar, Yashpal ; Abecassis, Michael ; Miller, Joshua. / HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance. In: Clinical transplants. 2013 ; pp. 145-156.
@article{aa85c2a2142347b699fcf39bd86c1b60,
title = "HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance.",
abstract = "In this chapter, we describe studies on non-chimeric human leukocyte antigen (HLA) identical tolerance and chimeric HLA disparate tolerance brought about by infusions of hematopoietic stem cells from the renal donor (DHSC). In our HLA identical series, 4 DHSC infusions were administered during the first 9 months posttransplant in a highly immunoregulatory environment using alemtuzumab induction and rapid conversion from early tacrolimus to mycophenolate and sirolimus. This resulted in the generation of recipient T regulatory cells accompanied by genomic indicators, but only transient chimerism. Seven of the first 12 recipients have been immunosuppression-free between 1 1/2 - 4 years with transplant biopsies free of rejection one year after immunosuppression withdrawal. The HLAdisparate group was treated by non-myeloablative conditioning consisting of: 200cGy whole body irradiation; fludarabine; cyclophosphamide; and, perioperative infusion of a product termed FCRx that contained DHSC, T cells, and a unique fraction of bone marrow derived CD8+TCR-alphabeta-negative cells. Five of the first 8 subjects became 100{\%} chimeric in the peripheral blood and have been immunosuppression-free for 2 to 4 years without graft-versus-host-disease and with normal function and transplant biopsies. An additional 12 recipients with shorter follow-up have had similar courses. Those with non-durable chimerism have not been able to have immunosuppression withdrawn but maintain normal renal transplant function. We conclude that non-HLA disparities in renal transplants between HLA identical pairs may not need durable chimerism to induce tolerance provided by DHSC and temporary immunosuppression supporting the development of regulatory T cells. However, more intense conditioning and infusion of FCRx leading to durable chimerism in the absence of graft versus host disease is necessary to induce tolerance in HLA disparate pairs.",
author = "Leventhal, {Joseph R.} and Mathew, {James M.} and Suzanne Ildstad and Salomon, {Daniel R.} and Kurian, {Sunil M.} and Manikkam Suthanthiran and Anat Tambur and John Friedewald and Lorenzo Gallon and Jane Charette and Josh Levitsky and Yashpal Kanwar and Michael Abecassis and Joshua Miller",
year = "2013",
month = "1",
day = "1",
language = "English",
pages = "145--156",
journal = "Clinical transplants",
issn = "0890-9016",
publisher = "UCLA Immunogenetics Center",

}

TY - JOUR

T1 - HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance.

AU - Leventhal, Joseph R.

AU - Mathew, James M.

AU - Ildstad, Suzanne

AU - Salomon, Daniel R.

AU - Kurian, Sunil M.

AU - Suthanthiran, Manikkam

AU - Tambur, Anat

AU - Friedewald, John

AU - Gallon, Lorenzo

AU - Charette, Jane

AU - Levitsky, Josh

AU - Kanwar, Yashpal

AU - Abecassis, Michael

AU - Miller, Joshua

PY - 2013/1/1

Y1 - 2013/1/1

N2 - In this chapter, we describe studies on non-chimeric human leukocyte antigen (HLA) identical tolerance and chimeric HLA disparate tolerance brought about by infusions of hematopoietic stem cells from the renal donor (DHSC). In our HLA identical series, 4 DHSC infusions were administered during the first 9 months posttransplant in a highly immunoregulatory environment using alemtuzumab induction and rapid conversion from early tacrolimus to mycophenolate and sirolimus. This resulted in the generation of recipient T regulatory cells accompanied by genomic indicators, but only transient chimerism. Seven of the first 12 recipients have been immunosuppression-free between 1 1/2 - 4 years with transplant biopsies free of rejection one year after immunosuppression withdrawal. The HLAdisparate group was treated by non-myeloablative conditioning consisting of: 200cGy whole body irradiation; fludarabine; cyclophosphamide; and, perioperative infusion of a product termed FCRx that contained DHSC, T cells, and a unique fraction of bone marrow derived CD8+TCR-alphabeta-negative cells. Five of the first 8 subjects became 100% chimeric in the peripheral blood and have been immunosuppression-free for 2 to 4 years without graft-versus-host-disease and with normal function and transplant biopsies. An additional 12 recipients with shorter follow-up have had similar courses. Those with non-durable chimerism have not been able to have immunosuppression withdrawn but maintain normal renal transplant function. We conclude that non-HLA disparities in renal transplants between HLA identical pairs may not need durable chimerism to induce tolerance provided by DHSC and temporary immunosuppression supporting the development of regulatory T cells. However, more intense conditioning and infusion of FCRx leading to durable chimerism in the absence of graft versus host disease is necessary to induce tolerance in HLA disparate pairs.

AB - In this chapter, we describe studies on non-chimeric human leukocyte antigen (HLA) identical tolerance and chimeric HLA disparate tolerance brought about by infusions of hematopoietic stem cells from the renal donor (DHSC). In our HLA identical series, 4 DHSC infusions were administered during the first 9 months posttransplant in a highly immunoregulatory environment using alemtuzumab induction and rapid conversion from early tacrolimus to mycophenolate and sirolimus. This resulted in the generation of recipient T regulatory cells accompanied by genomic indicators, but only transient chimerism. Seven of the first 12 recipients have been immunosuppression-free between 1 1/2 - 4 years with transplant biopsies free of rejection one year after immunosuppression withdrawal. The HLAdisparate group was treated by non-myeloablative conditioning consisting of: 200cGy whole body irradiation; fludarabine; cyclophosphamide; and, perioperative infusion of a product termed FCRx that contained DHSC, T cells, and a unique fraction of bone marrow derived CD8+TCR-alphabeta-negative cells. Five of the first 8 subjects became 100% chimeric in the peripheral blood and have been immunosuppression-free for 2 to 4 years without graft-versus-host-disease and with normal function and transplant biopsies. An additional 12 recipients with shorter follow-up have had similar courses. Those with non-durable chimerism have not been able to have immunosuppression withdrawn but maintain normal renal transplant function. We conclude that non-HLA disparities in renal transplants between HLA identical pairs may not need durable chimerism to induce tolerance provided by DHSC and temporary immunosuppression supporting the development of regulatory T cells. However, more intense conditioning and infusion of FCRx leading to durable chimerism in the absence of graft versus host disease is necessary to induce tolerance in HLA disparate pairs.

UR - http://www.scopus.com/inward/record.url?scp=84906952525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906952525&partnerID=8YFLogxK

M3 - Article

SP - 145

EP - 156

JO - Clinical transplants

JF - Clinical transplants

SN - 0890-9016

ER -